ArticleNephrology (Carlton, Vic.)2026
Nephrogenic Syndrome of Inappropriate Antidiuresis: Case Report and Genetic Perspectives.
Article in Nephrology (Carlton, Vic.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo report a case of nephrogenic syndrome of inappropriate antidiuresis (NSIAD) caused by a de novo hemizygous hotspot variant (c.409C>T p.R137C) in the AVPR2 gene in a young male child, and to discuss the diagnostic approach, therapeutic management, and follow-up of NSIAD.
methodsA 3-year and 2-month-old male child presenting with intermittent convulsions persisting for over one year and chronic hyponatremia was clinically evaluated. Genetic testing was performed to identify potential causative variants. Water restriction therapy was implemented, with the patient spontaneously limiting water intake to prevent infections and regulating fluid intake during illnesses. Follow-up evaluations were conducted at 3 and 6 months.
resultsGenetic testing identified a de novo hemizygous hotspot variant, c.409C>T (p.R137C), in the AVPR2 gene. The patient adhered to spontaneous water restriction and regulated fluid intake during illnesses. Follow-up evaluations at 3 and 6 months demonstrated normal serum sodium levels, with no recurrence of convulsions or other symptoms.
conclusionNSIAD should be included in the differential diagnosis of hyponatremia of unknown etiology. Genetic testing is crucial for achieving an early diagnosis, optimizing treatment regimens, and enhancing treatment compliance. Water restriction therapy, under careful monitoring, remains a safe and effective treatment modality, particularly during periods of illness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.